Pharmacyclics — Technical Presentation (December 2012)
18 slides from Pharmacyclics's technical presentation, Dec 10, 2012
Slide 1: Disclosures
Disclosures NATHAN FowLer, MD RESEARCH FUNDING: Pharmacyclics EMPLOYEE: None * STOCKHOLDER: None CONSULTANT: None SCIENTIFIC ADVISORY BOARD: Pharmacyclics
Slide 2: The BTK Inhibitor Ibrutinib (PCI-32765) is Active and Tolerated in Relapsed Follicular Lymphoma
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Active and Tolerated in Relapsed Follicular Lymphoma (FL) Nathan Fowler MD', Ranjana Advani MD?, Jeff Sharman MD®, Sonali M, Smith MD*, Jesse McGreivy MD®, Lori Kunkel MD°, Vina Troung®, Cathy Zhou’, Thomas Boyd MD* ‘Dept. of Lymp
Slide 3: Bruton's Tyrosine Kinase (BTK): A Critical Kinase
Bruton’s Tyrosine Kinase (BTK): A Critical Kinase for * Bruton’s tyrosine kinase (BTK) is an essential element of the BCR signaling pathway + Inhibitors of BTK block BCR signaling and induce apoptosis + PCI-32765 (ibrutinib) forms bond with cysteine-481 in BTK + Highly potent BTK inhibition at ICs.
Slide 4: Study Design
Study Design - Dose Escalation Study — Cohorts: n 2 6 patients — Escalate to maximum tolerated dose (MTD) or 3 dose levels above complete active site occupancy — Tumor assessment performed every 2 cycles » Dosing — 1.25, 2.5, 5.0, 8.3, 12.5 mg/kg/d po (Cycle = 28 days + 7 days rest) — 2 continuous d
Slide 5: Key Inclusion / Exclusion Criteria
Key Inclusion / Exclusion Criteria » Recurrent B-cell malignancies - ECOGSs1 * Prior treatment: 21 and < 4 (no limit for CLL) » Measurable disease — 22cm diameter for NHL — 26000 leukemia cells/mm? for CLL — IgM level 2 1000 mg/dL + BM infiltration for Waldenstrém’s macroglobulinemia » No known cent
Slide 6: Objectives
Objectives - Primary Objectives — Establish the safety and the MTD — Determine the pharmacokinetics of ibrutinib — Measure pharmacodynamic parameters, including drug occupancy of BTK * Secondary Objective — Evaluate tumor response
Slide 7: Follicular Lymphoma Baseline Characteristics
Follicular Lymphoma Baseline Characteristics (a sub-group of pts enrolled in PCYC 04753 study) (N=16) Median age, years (range) 60 (41-71) Male 50% Time from diagnosis, months (range) 54 (19-186) Median number of prior therapies (range) 3 (1-5) Auto-stem cell transplant, % 6% Alkylators 88% Anthracy
Slide 8: Follicular Lymphoma Baseline Disease Characteristics
Follicular Lymphoma Baseline Disease Characteristics Characteristics (N=16) Stage at diagnosis land Il 3 (19%) mm 5 (31%) IV 7 (44%) Missing 1 (6%) Follicular grade 4 7 (44%) 2 5 (31%) 3 3 (19%) Missing 1 (6%)
Slide 9: BTK Occupancy
BTK Occupancy Comparison of the Degree of BTK Occupancy by Ibrutinib at Each Dose-Level Cohort in the Study = 104 4! 1 “TE UT) “1 | 4 g “2 Te Te V4 5 80 é s ° & 60 s Ss 40 S . ~~ 20 i a ° Lr Ca a er aR ee es a ee ss ys ee NS ~~ ee SS ~~ ee es ye ee ss ye ee ss oS Cohort! Cohort Il Cohort Ill CohortI
Slide 10: Adverse Events >10%
Adverse Events >10% (includes both related and unrelated AEs) Hematologic AEs Neutropenia 13% Grade 1 All grades diade 3 Anemia 13% uGrade 3 Non-Hematologic AEs 0 20 40 60 80 100 > Grade 1 Upper Respiratory tract infection Vomiting Headache Myalgia Cough Fatigue 0 2 40 60 80 100 All Grade 4 AEs Perc
Slide 11: Median Change in Absolute Lymphocyte Count in FL Patients
Median Absolute Counts (10*g/L) Median Change in Absolute Lymphocyte Count in FL Patients o2 No significant change in peripheral NK, T, or B cell levels ei io 6 44 2 Visits "
Slide 12: Median Change in Absolute Neutrophil Count in FL Patients
Median Change in Absolute Neutrophil Count in FL Patients Median Absolute Counts (104g/L) Prophylactic growth factor not used eis yo 434g A 44 Visits 2
Slide 13: Median Change in Platelet Count in FL Patients
Median Change in Platelet Count in FL Patients a Median Absolute Counts (10*g/L) a Visits
Slide 14: Response Results (median observation time ~7 months)
(median observation time ~7 months) (n=16) Overall response rate (Gi ee 7 (44%) Complete response (CR) 3 (19%) Partial response (PR) 4 (25%) Median DOR, months 12.3 Median time to first response (range), months 4,7 (2-12) Median time to first PR (range), months 4.6 (2-11) Median time to first CR(ran
Slide 15: Efficacy in FL Patients
Efficacy in FL Patients (Evaluable population with 2 1 response assessment, n=15) =CR &PR 100 = # 80 ro 2 & 60 55% 56% 6 € 8 40 g 25% a 0+ 1.25 mg/kg/day 22.5 mg/kg/day 25.0 mg/kg/day (n=4) (n=11) (n=9) Median DOR: NE 10.3 months 12.3 months Median PFS: NE 13.4 months 19.6 months 8
Slide 16: Follicular: Time on Study Treatment by Best Response
Follicular Time on Study Treatment by Best Response = Patient still on ibrutinib 6
Slide 17: Conclusions
Conclusions Ibrutinib in relapsed follicular lymphoma patients is well tolerated and active No cumulative toxicity with extended dosing Based on drug occupancy and clinical responses, the dose of 560 mg is recommended for future FL studies Response improved with continued treatment in some patients
Slide 18: Acknowledgement
Acknowledgement > All the patients and their families who participated in the study - Investigators and clinical research staff from all the clinical centers * Pharmacyclics 8
Pharmacyclics — Technical Presentation (December 2012) on 6ix